Rosiglitazone is a synthetic agonist of peroxisome proliferator-activated receptor (PPAR)-γ, which is commonly used to reverse insulin resistance in patients with type II diabetes [43]. This evidence concerns the gene PPARG and type 2 diabetes mellitus.